VCNX vs. PHIO, BCDA, PHXM, AIMD, CSCI, TRIB, GLYC, NKGN, KPRX, and BTAI
Should you be buying Vaccinex stock or one of its competitors? The main competitors of Vaccinex include Phio Pharmaceuticals (PHIO), BioCardia (BCDA), PHAXIAM Therapeutics (PHXM), Ainos (AIMD), COSCIENS Biopharma (CSCI), Trinity Biotech (TRIB), GlycoMimetics (GLYC), NKGen Biotech (NKGN), Kiora Pharmaceuticals (KPRX), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical products" industry.
Vaccinex vs. Its Competitors
Phio Pharmaceuticals (NASDAQ:PHIO) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.
Phio Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Vaccinex has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.
Phio Pharmaceuticals has higher earnings, but lower revenue than Vaccinex. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.
In the previous week, Phio Pharmaceuticals' average media sentiment score of 0.50 beat Vaccinex's score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.
Phio Pharmaceuticals currently has a consensus price target of $14.00, suggesting a potential upside of 475.18%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Phio Pharmaceuticals is more favorable than Vaccinex.
Vaccinex's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.
57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 50.1% of Vaccinex shares are held by institutional investors. 0.6% of Phio Pharmaceuticals shares are held by company insiders. Comparatively, 51.5% of Vaccinex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Phio Pharmaceuticals beats Vaccinex on 8 of the 13 factors compared between the two stocks.
Get Vaccinex News Delivered to You Automatically
Sign up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VCNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vaccinex Competitors List
Related Companies and Tools
This page (NASDAQ:VCNX) was last updated on 7/5/2025 by MarketBeat.com Staff
Free VCNX Stock Alerts